

ESC/EACTS guidelines 2018

Revaskularizace u SS

Petr Kala
IKK FN Brno

Kardio 35 - ČKS, 3.11.2018

Petr Kala

- **bez konfliktu zájmů,**
- **reviewer za ČKS těchto guidelines**



ESC

European Society
of Cardiology

European Heart Journal (2018) 00, 1–96
doi:10.1093/eurheartj/ehy394

ESC/EACTS GUIDELINES

2018 ESC/EACTS Guidelines on myocardial revascularization

The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS)

Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI)

Authors/Task Force Members: Franz-Josef Neumann* (ESC Chairperson) (Germany), Miguel Sousa-Uva*¹ (EACTS Chairperson) (Portugal), Anders Ahlsson¹ (Sweden), Fernando Alfonso (Spain), Adrian P. Banning (UK), Umberto Benedetto¹ (UK), Robert A. Byrne (Germany), Jean-Philippe Collet (France), Volkmar Falk¹ (Germany), Stuart J. Head¹ (The Netherlands), Peter Jüni (Canada), Adnan Kastrati (Germany), Akos Koller (Hungary), Steen D. Kristensen (Denmark), Josef Niebauer (Austria), Dimitrios J. Richter (Greece), Petar M. Seferović (Serbia), Dirk Sibbing (Germany), Giulio G. Stefanini (Italy), Stephan Windecker (Switzerland), Rashmi Yadav¹ (UK), Michael O. Zembala¹ (Poland)

Document Reviewers: William Wijns (ESC Review Co-ordinator) (Ireland), David Glineur¹ (EACTS Review Co-ordinator) (Canada), Victor Aboyans (France), Stephan Achenbach (Germany), Stefan Agewall (Norway), Felicita Andreotti (Italy), Emanuele Barbato (Italy), Andreas Baumbach (UK), James Brophy (Canada), Héctor Bueno (Spain), Patrick A. Calvert (UK), Davide Capodanno (Italy), Piroze M. Davierwala¹

Kritéria pro výběr typu revaskularizace (PCI vs CABG)

Recommendations on criteria for the choice between coronary artery bypass grafting and percutaneous coronary intervention

Recommendations	Class ^a	Level ^b
Assessment of surgical risk^c		
It is recommended that the STS score is calculated to assess in-hospital or 30 day mortality, and in-hospital morbidity after CABG. ^{112,114,138}	I	B
Calculation of the <u>EuroSCORE II</u> score may be considered to assess in-hospital mortality after CABG. ¹¹²	IIb	B
Assessment of CAD complexity		
In patients with LM or <u>multivessel</u> disease, it is recommended that the SYNTAX score is calculated to assess the <u>ana-tomical</u> complexity of CAD and the long-term risk of mortality and morbidity after PCI. ^{117–124}	I	B
When considering the decision between CABG and PCI, completeness of revascularization should be prioritized. ^{131,132,134–136}	IIa	B



EuroSCORE = European System for Cardiac Operative Risk Evaluation; CABG = coronary artery bypass grafting; CAD = coronary artery disease; LM = left main; PCI = percu-taneous coronary intervention; STS = Society of Thoracic Surgeons; SYNTAX = Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery.

^aClass of recommendation.

^bLevel of evidence.

^cLevel of evidence refers to prediction of outcomes.

Kritéria pro výběr typu revaskularizace (PCI vs CABG) Syntax I skóre



Kritéria pro výběr typu revaskularizace

Syntax II skóre




Figure SYNTAX Score II nomogram for bedside application

Total number of points for 8 factors can be used to accurately predict 4-year mortality for the individual patient proposing to undergo for CABG or PCI. For example, a 60 year old man with an anatomical SYNTAX score of 30, unprotected left main coronary artery disease, creatinine clearance of 60 mL/min, an LVEF of 50%, and COPD, would have 41 points (predicted 4-year mortality 16-3%) to undergo CABG and 33 points (predicted 4-year mortality 8-7%) to undergo PCI respectively. The same example without COPD included would lead to identical points (29 points) and 4-year mortality predictions (6-3%) for CABG and PCI. COPD defined with EuroSCORE^{II} definition, long-term use of bronchodilators or steroids for lung disease. PVD defined according to ARTS I^{II} definition, aorta and arteries other than coronaries, with exercise-related claudication, or revascularisation surgery, or reduced or absent pulsation, or angiographic stenosis of more than 50%, or combinations of these characteristics. CABG=coronary artery bypass surgery. PCI=percutaneous coronary intervention. CrCl=creatinine clearance. LVEF=left ventricular ejection fraction. Left main=unprotected left main coronary artery disease. 3VD=three-vessel disease. COPD=chronic obstructive pulmonary disease. PVD=peripheral vascular disease. *Because of the rarity of complex coronary artery disease in premenopausal women, mortality predictions in younger women are predominantly based on the linear relation of age with mortality. The differences in mortality predictions in younger women between CABG and PCI will therefore be affected by larger 95% CIs than those in older women.

Kritéria pro výběr typu revaskularizace STS a EuroScore II



Variable	Preoperative score	Combined score
Age (for each five years over 55 years)	1	1
BMI 30–40 kg/m ²	4	3
BMI 40 kg/m ²	9	8
Diabetes	3	3
Renal failure	4	4
Congestive heart failure	3	3
Peripheral vascular disease	2	2
Female gender	2	2
Chronic lung disease	2	3
Cardiogenic shock	6	n/a
Myocardial infarction	2	n/a
Concomitant surgery	4	n/a
Perfusion time 100–200 minutes	n/a	3
Perfusion time 200–300 minutes	n/a	7
Intra-aortic balloon pump	n/a	5

STS, Society for Thoracic Surgeons; BMI, body mass index.

Important: The previous additive ¹ and logistic ² EuroSCORE models are out of date. A new model has been prepared from fresh data and is launched at the 2011 EACTS meeting in Lisbon. The model is called EuroSCORE II ³ - this online calculator has been updated to use this new model. If you need to calculate the older "additive" or "logistic" EuroSCORE please visit the old calculator by [clicking here](#).

Patient related factors			Cardiac related factors		
Age ¹ (years)	<input type="text" value="0"/>	<input type="text" value="0"/>	NYHA	<input type="text" value="select"/>	<input type="text" value="0"/>
Gender	<input type="text" value="select"/>	<input type="text" value="0"/>	CCS class 4 angina ⁸	<input type="text" value="no"/>	<input type="text" value="0"/>
Renal impairment ² <small>See calculator below for creatinine clearance</small>	<input type="text" value="normal (CC >85ml/min)"/>	<input type="text" value="0"/>	LV function	<input type="text" value="select"/>	<input type="text" value="0"/>
Extracardiac arteriopathy ³	<input type="text" value="no"/>	<input type="text" value="0"/>	Recent MI ⁹	<input type="text" value="no"/>	<input type="text" value="0"/>
Poor mobility ⁴	<input type="text" value="no"/>	<input type="text" value="0"/>	Pulmonary hypertension ¹⁰	<input type="text" value="no"/>	<input type="text" value="0"/>
Previous cardiac surgery	<input type="text" value="no"/>	<input type="text" value="0"/>	Operation related factors		
Chronic lung disease ⁵	<input type="text" value="no"/>	<input type="text" value="0"/>	Urgency ¹¹	<input type="text" value="elective"/>	<input type="text" value="0"/>
Active endocarditis ⁶	<input type="text" value="no"/>	<input type="text" value="0"/>	Weight of the intervention ¹²	<input type="text" value="isolated CABG"/>	<input type="text" value="0"/>
Critical preoperative state ⁷	<input type="text" value="no"/>	<input type="text" value="0"/>	Surgery on thoracic aorta	<input type="text" value="no"/>	<input type="text" value="0"/>
Diabetes on insulin	<input type="text" value="no"/>	<input type="text" value="0"/>			
EuroSCORE II	<input type="text" value="0"/>				
<small>Note: This is the 2011 EuroSCORE II</small> <input type="button" value="Calculate"/> <input type="button" value="Clear"/>					

Recommendations	Class ^a	Level ^b
Non-invasive stress imaging (CMR, stress echocardiography, SPECT, or PET) may be considered for the assessment of myocardial ischaemia and viability in patients with HF and CAD (considered suitable for coronary revascularization) before the decision on revascularization. ^{9–11}	IIb	B

Recommendations	Class ^a	Level ^b
When evidence of ischaemia is not available, FFR or iwFR are recommended to assess the haemodynamic relevance of intermediate-grade stenosis. ^{15,17,18,39}	I	A
FFR-guided PCI should be considered in patients with multivessel disease undergoing PCI. ^{29,31}	IIa	B
IVUS should be considered to assess the severity of unprotected left main lesions. ^{35–37}	IIa	B

Revaskularizace „prognostická“ a „symptomatická“

Extent of CAD (anatomical and/or functional)		Class ^a	Level ^b
For prognosis	Left main disease with stenosis >50%. ^{c68–71}	I	A
	Proximal LAD stenosis >50%. ^{c62,68,70,72}	I	A
	Two- or three-vessel disease with stenosis >50% with impaired LV function (LVEF ≤35%). ^{c61,62,68,70,73–83}	I	A
	Large area of ischaemia detected by functional testing (>10% LV) or abnormal invasive FFR. ^{d24,59,84–90}	I	B
	Single remaining patent coronary artery with stenosis >50%. ^c	I	C
For symptoms	Haemodynamically significant coronary stenosis ^c in the presence of limiting angina or angina equivalent, with insufficient response to optimized medical therapy. ^{e24,63,91–97}	I	A

1. Revaskularizace pacientů s chronickým SS a EF ≤35%

Recommendations	Class ^a	Level ^b
In patients with severe LV systolic dysfunction and coronary artery disease suitable for intervention, myocardial revascularization is recommended. ^{81,250}	I	B
CABG is recommended as the first revascularization strategy choice in patients with multivessel disease and acceptable surgical risk. ^{68,81,248,255}	I	B

In patients with one- or two-vessel disease, PCI should be considered as an alternative to CABG when complete revascularization can be achieved.	IIa	C
In patients with three-vessel disease, PCI should be considered based on the evaluation by the Heart Team of the patient's coronary anatomy, the expected completeness of revascularization, diabetes status, and comorbidities.	IIa	C
LV aneurysmectomy during CABG should be considered in patients with NYHA class III/IV, large LV aneurysm, large thrombus formation, or if the aneurysm is the origin of arrhythmias.	IIa	C

1. Revaskularizace pacientů s chronickým SS a EF ≤35%

STICH trial





Figure 1. Randomization and Follow-up.
CABG denotes coronary-artery bypass grafting.



1. Revaskularizace pacientů s chronickým SS a EF ≤35%

<p>Surgical ventricular restoration during CABG may be considered in selected patients treated in centres with expertise.^{252–254,256,257}</p>	<p>IIb</p>	<p>B</p>
---	------------	----------

The STICH trial revealed no difference in the primary outcome (total mortality or cardiac hospitalization) between patients randomly allocated to CABG vs. combined CABG and SVR.²⁵²

Subgroup analyses of patients with a less dilated LV and better LVEF showed benefit from SVR.²⁵³

In the STICH trial, a post-operative LV end-systolic volume index < 70 mL/m², after CABG plus SVR, resulted in improved survival compared with CABG alone.^{252,254}
In experienced centres, SVR may be done at the time of CABG if HF symptoms are more predominant than angina, and if myocardial scar and moderate LV remodelling are present.

2. Revaskularizace pacientů s akutním SS a kardiogenním šokem




Figure 6 Algorithm for the management of patients with cardiogenic shock.


Management pacientů v kardiogenním šoku



Recommendations	Classa	Levelb
Emergency coronary angiography is indicated in patients with acute heart failure or cardiogenic shock complicating ACS. 258,269	I	B
Emergency PCI of the culprit lesion is indicated for patients with cardiogenic shock due to STEMI or NSTEMI-ACS, independent of time delay of symptom onset, if coronary anatomy is amenable to PCI. 258	I	B
Emergency CABG is recommended for patients with cardiogenic shock if the coronary anatomy is not amenable to PCI. 258	I	B
In cases of haemodynamic instability, emergency surgical or catheter-based repair of mechanical complications of ACS is indicated, as decided by the Heart Team.	I	C


Continuous Flow Pumps

Pulsatile




IABP

Axial-Flow




Impella CP




PHP *

Centrifugal Flow



TandemHeart



VA-ECMO

Intracorporeal

Extracorporeal

Kapur N, ACC 2016

* Investigational

Right Ventricle

Axial Flow




Impella RP

Centrifugal Flow



VA-ECMO



Tandem pRVAD




Protek Oxy-RVAD

Primární PCI: strategie a technika


Recommendations	Class ^a	Level ^b
Strategy		
Routine revascularization of non-IRA lesions should be considered in patients with multivessel disease before hospital discharge. ^{211–214}	IIa	A
CABG should be considered in patients with ongoing ischaemia and large areas of jeopardized myocardium if PCI of the IRA cannot be performed.	IIa	C
In cardiogenic shock, routine revascularization of non-IRA lesions is not recommended during primary PCI. ¹¹⁰	III	B
Technique		
Routine use of thrombus aspiration is not recommended. ^{223–226,228}	III	A

Primární PCI: Culprit SHOCK trial

RCT, 706 pacientů, 14 center



Indikace PCI vs CABG




CABG = coronary artery bypass grafting; Cx = circumflex; DAPT = dual antiplatelet therapy; EF = ejection fraction; LAD = left anterior descending coronary artery; LIMA = left internal mammary artery; LV = left ventricular; MVD = multivessel coronary artery disease; PCI = percutaneous coronary intervention; PDA = posterior descending artery; RA = radial artery; RIMA = right internal mammary artery; SYNTAX = Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery.
 „Consider no-touch off-pump CABG in case of porcelain aorta.“

Figure 3 Aspects to be considered by the Heart Team for decision-making between percutaneous coronary intervention and coronary artery bypass grafting among patients with stable multivessel and/or left main coronary artery disease.

CAVE: chybí RCT porovnávající PCI vs CABG u pacientů s CHSS!

Chirurgická revaskularizace



Co je nového v r. 2018?



Calculation of the Syntax Score, if left main or multivessel revascularization is considered	Completeness of revascularization prioritized, when considering CABG vs PCI	Routine non-invasive imaging surveillance in high-risk patients 6 months after revascularization
Radial access as standard approach for coronary angiography and PCI	NOAC preferred over VKA in patients with non-valvular AF requiring anticoagulation and antiplatelet treatment	Double-kissing crush technique preferred over provisional T-stenting in true left main bifurcations.
DES for any PCI	No-touch vein technique, if open vein harvesting for CABG	Cangrelor in P2Y ₁₂ -inhibitor naïve patients undergoing PCI
Systematic re-evaluation of patients after myocardial revascularization	Annual operator volume for left main PCI of at least 25 cases per year	GP IIb/IIIa inhibitors for PCI in P2Y ₁₂ -inhibitor naïve patients with ACS undergoing PCI
Stabilised NSTEMI-ACS patients: revascularization strategy according to principles for SCAD	Pre- and post-hydration with isotonic saline in patients with moderate or severe CKD if the expected contrast volume is >100 mL	Dabigatran 150-mg dose preferred over 110-mg dose when combined with single antiplatelet therapy after PCI
Use of the radial artery grafts over saphenous vein grafts in patients with high-degree stenosis		De-escalation of P2Y ₁₂ inhibitor guided by platelet function testing in ACS patients
Myocardial revascularization in patients with CAD, heart failure, and LVEF ≤35% CABG preferred		Routine revascularization of non-IRA lesions in myocardial infarction with cardiogenic shock
PCI as alternative to CABG		Current generation BRS for clinical use outside clinical studies
<p>The figure does not show changes compared with the 2014 version of the Myocardial Revascularization Guidelines that were due to updates for consistency with other ESC Guidelines published since 2014.</p>		

ACS = acute coronary syndromes; AF = atrial fibrillation; BRS = bioresorbable scaffolds; CABG = coronary artery bypass grafting; CAD = coronary artery disease; CKD = chronic kidney disease; DES = drug-eluting stents; FFR = fractional flow reserve; GP = glycoprotein; IRA = infarct-related artery; LVEF = left ventricular ejection fraction; NOAC = non-vitamin K oral anticoagulants; NSTEMI = non-ST-elevation; PCI = percutaneous coronary intervention; SCAD = stable coronary artery disease; VKA = vitamin K antagonists.

Figure 1 New recommendations.

Co se změnilo v r. 2018?



UPGRADES

For PCI of bifurcation lesions, stent implantation in the main vessel only, followed by provisional balloon angioplasty with or without stenting of the side branch

Immediate coronary angiography and revascularization, if appropriate, in survivors of out-of-hospital cardiac arrest and an ECG consistent with STEMI

Assess all patients for the risk of contrast-induced nephropathy

OCT for stent optimization

DOWNGRADES

Distal protection devices for PCI of SVG lesions

Bivalirudin for PCI in NSTEMI-ACS

Bivalirudin for PCI in STEMI

PCI for MVD with diabetes and SYNTAX score < 23

Platelet function testing to guide antiplatelet therapy interruption in patients undergoing cardiac surgery

EuroSCORE II to assess in-hospital mortality after CABG

Co nesmíte minout v Brně (nejen v r. 2018)? 😊



Ludwig Mies van der Rohe ve vile Tugendhat v únoru 1931, foto: Fritz Tugendhat